Company Filing History:
3 out of 28 
1 out of 17 Years Active: 2022-2024
Title: Luc Van Rompaey: Innovator in Combination Therapies for Malignancies
Introduction
Luc Van Rompaey is a notable inventor based in Ghent, Belgium. He has made significant contributions to the field of oncology, particularly in the development of combination therapies for the treatment of malignancies. With a total of three patents to his name, his work focuses on innovative approaches to combat various forms of cancer.
Latest Patents
One of his latest patents is centered around CD70 combination therapy. This invention relates to combination therapies for the treatment of malignancy, specifically targeting myeloid malignancies such as acute myeloid leukemia (AML). The therapies may include an antibody molecule that binds to CD70 and at least one antibody molecule that targets leukemic stem cells. Preferred targets for these stem cells include TIM-3, IL1R3/IL1RAP, and CD47. Another significant patent also focuses on CD70 combination therapy, providing methods for treating malignancies like AML, myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), chronic myeloid leukemia (CML), and chronic myelomonocytic leukemia (CMML). This combination may involve an antibody or antigen-binding fragment that binds to CD70, along with a BCL-2 inhibitor, such as venetoclax, which can lead to synergistic treatment outcomes for AML.
Career Highlights
Luc Van Rompaey has worked with prominent organizations, including Argenx Bv and the University of Bern. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research in cancer therapies.
Collaborations
Some of his notable coworkers include Mahan Moshir and Tim Delahaye. Their collaborative efforts have further advanced the research and development of innovative cancer treatments.
Conclusion
Luc Van Rompaey's work in combination therapies for malignancies showcases his dedication to improving cancer treatment options. His patents reflect a commitment to innovation in the medical field, particularly in addressing complex diseases like acute myeloid leukemia.